AUS
NZ
UK
CA
USA
IND
Headlines
- Amneal Pharmaceuticals' shares rose 29% in the past month following multiple FDA approvals, including a novel Parkinson's disease treatment.
- The company achieved robust revenue growth in Q2 2024, driven by new product launches and increased demand in neurology and endocrinology.
- Amneal's strategic moves, including the launch of a generic version of Propofol and an enhanced product portfolio, are positioning it for continued growth.
Amneal Pharmaceuticals (NYSE:AMRX), a commercial-stage company with a focus on generics and specialty pharmaceutical products, has seen its shares rise by 29.3% over the past month. This impressive surge follows a series of positive regulatory updates and strong quarterly performance.
FDA Approval for Parkinson’s Disease Treatment
In August 2024, Amneal received FDA approval for IPX203, a novel oral formulation of carbidopa/levodopa (CD/LD) designed for the treatment of Parkinson’s Disease (PD). Marketed under the brand name Crexont, this formulation combines immediate-release granules with extended-release pellets. The approval was based on favorable results from the pivotal phase III RISE-PD study, which demonstrated a significant improvement in Good On time—a period when PD symptoms are effectively controlled without troublesome side effects—compared to existing short-acting treatments. Crexont is expected to launch in the United States in September 2024.
Expansion with Generic Propofol
Amneal also announced FDA approval for its abbreviated new drug application (ANDA) for Propofol Injectable Emulsion USP, a generic version of a widely-used intravenous anesthetic. Amid ongoing supply chain challenges, Propofol has been listed as a shortage by the American Society of Health-System Pharmacists. Amneal plans to manufacture this product in-house on a dedicated production line, aiming to ensure a stable supply with a projected launch in the fourth quarter of 2024.
Strong Financial Performance
Amneal’s robust financial performance in Q2 2024 further contributed to the stock’s upward momentum. The company reported net revenues of $702 million, marking a 17% year-over-year increase. This growth was driven by the success of its oncology biosimilars, new product launches, and the continued strength of its Neurology and Endocrinology segments. The company has also raised its financial outlook for the full year, signaling confidence in its growth trajectory.
Amneal’s expanding portfolio of generics and specialty products continues to garner attention, and its strategic initiatives are expected to drive further success in the coming months.
